ArticleScientific reports2026
A critical role for STAT3 Thr714 phosphorylation in NPM-ALK-driven tumorigenesis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The oncogenic fusion protein NPM-ALK drives anaplastic large cell lymphoma (ALCL) by activating the transcription factor STAT3. While STAT3 phosphorylation at Y705 and S727 is well characterized, the present study defines a mechanistic role for phosphorylation at T714 in supporting full STAT3 functionality. In NPM-ALK-positive ALCL cells, STAT3 is phosphorylated at Y705, S727, and T714, and this is suppressed by ALK inhibition. Enforced NPM-ALK expression in Ba/F3 cells induces phosphorylation at all three sites in a kinase-dependent manner. To investigate the role of T714, wild-type STAT3 or a T714A mutant was reconstituted into STAT3-knockdown Ba/F3 cells expressing NPM-ALK. Wild-type STAT3 underwent Y705 and S727 phosphorylation and nuclear translocation, whereas the T714A mutant was phosphorylated at S727 only and failed to translocate. The reduced expression of STAT3 target genes (Cyclin D1, Pim1, Pim2, and Socs3) with STAT3 knockdown was restored by wild-type STAT3, but not by the T714A mutant. In vivo, STAT3 knockdown suppressed tumor formation and hepatosplenomegaly in mice inoculated with Ba/F3 cells expressing NPM-ALK, and these phenotypes were rescued by wild-type STAT3, but not by the T714A mutant. These findings indicate that STAT3 phosphorylation at T714 is required for subsequent Y705 phosphorylation, nuclear translocation, and transcriptional activation specifically within the context of NPM-ALK-mediated signaling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.